BOTHELL, WA. -- May 15, 2019 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment of Christopher Holt as Site Head/General
Manager of its Bothell, Washington operations. Mr. Holt will provide leadership and site management to
ensure AGC Biologics’ continued execution of world-class contract development and manufacturing
services.
Mr. Holt brings more than 20 years of leadership experience in the biotechnology and manufacturing
industry, having worked for Lonza, DSM/Patheon and GlaxoSmithKline in the US and Europe.
“We are pleased that Chris Holt is bringing his deep knowledge and expertise to AGC Biologics.” saidPatricio Massera, AGC Biologics Chief Executive Officer. “The role of Site Head/General Manager in our
global headquarters, located in or Bothell, Washington facility is essential to our operation’s expansion and
growth. Chris’ expertise and experience in our industry and strong leadership skills are an excellent asset
to lead our Bothell site in growth and achievement of our stated goals and objectives.”
About AGC Biologics
AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a
strong commitment to deliver the highest standard of service to our clients and partners. AGC Biologics is
the product of the convergence and integration of Asahi Glass Company (AGC) Bioscience, Biomeva
GmbH, and CMC Biologics. The company currently employs more than 850 employees worldwide. Our
extensive network spans three continents, with cGMP-compliant facilities in Seattle, WA; Berkeley, CA;
Copenhagen, Denmark; Heidelberg, Germany; Yokohama, Japan; and Chiba, Japan.
AGC Biologics offers deep industry expertise and unique customized services for the scale-up and cGMP
manufacture of protein-based therapeutics; from pre-clinical to commercial production, for mammalian and
microbial. Our integrated service offerings include cell line development, bioprocess development,
formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and
protein expression — including our proprietary CHEF1® Expression System for mammalian production.
Further information can be found at www.agcbio.com.
